Ajinomoto Bio-Pharma Services vs Pharmaron Biologics: CDMO Comparison
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Pharmaron Biologics on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron Biologics has more FDA inspections on record (3 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Pharmaron Biologics does not.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Pharmaron Biologics qualify as AAV manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Ajinomoto Bio-Pharma Services and Pharmaron Biologics qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Ajinomoto Bio-Pharma Services vs Pharmaron Biologics
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Pharmaron Biologics?
Both Ajinomoto Bio-Pharma Services and Pharmaron Biologics maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Pharmaron Biologics has 3.
How do Ajinomoto Bio-Pharma Services and Pharmaron Biologics compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Pharmaron Biologics holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Ajinomoto Bio-Pharma Services or Pharmaron Biologics?
Both Ajinomoto Bio-Pharma Services and Pharmaron Biologics are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 86/100 and Pharmaron Biologics carries 86/100 — essentially tied for Pharmaron Biologics. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →